Conditions: Attention Deficit Hyperactivity Disorder
Keywords: CLONICEL Attention Deficit Hyperactivity Disorder clonidine HCl sustained release
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 303
Healthy volunteers: no

Brief summary:
The purpose of this 12-month, multi-center, open-label study is to evaluate the safety of CLONICEL (clonidine HCl sustained release) when administered chronically under regular clinical conditions either as monotherapy or in combination with stimulant therapy to children and adolescents with attention deficit hyperactivity disorder (ADHD).

Detailed description:

Arms:
arm 1: CLONICEL (Clonidine HCl sustained release)

Interventions: intervention 1: CLONICEL (Clonidine HCl sustained release)
Intervention descriptions: intervention 1: 0.1 mg for 1 week; the dose may be escalated to 0.2 mg/day at week 2, 0.3 mg/day at week 3, and 0.4 mg/day at week 4

Protocol document: